Ibio (IBIO) AI Stock Analysis

• Market Cap: $18.93M
• Dividend Yield: N/A
• Average Volume (3M): 1.58M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: 77.78%
• EPS Growth: 84.08%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 19,654,636
• 10 Day Avg. Volume: 653,606
• 30 Day Avg. Volume: 1,582,058
• PEG Ratio: 0.00
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: 19.89
• Enterprise Value/Gross Profit: 6.67
• Enterprise Value/Ebitda: -0.49
• 1Y Price Target: $3.30
• Price Target Upside: 243.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: ―

IBIO's overall score is heavily impacted by significant financial challenges, including negative earnings and cash flow issues. The weak technical outlook and poor valuation metrics further weigh down the score. However, recent strategic corporate events provide some optimism for future growth, but they are not enough to offset the current financial difficulties.

Positive Factors

Strategic Licensing Agreement

This licensing agreement expands iBio's pipeline in the obesity treatment market, potentially enhancing its market position and long-term growth prospects.

Advancements in Obesity Antibody Programs

Advancements in obesity treatment programs suggest potential for new revenue streams and strengthen iBio's competitive position in the biopharmaceutical market.

Transfer to Nasdaq

Transferring to Nasdaq could increase visibility and attract institutional investors, potentially improving liquidity and market perception.

Negative Factors

Consistent Financial Losses

Ongoing financial losses and declining revenue indicate operational inefficiencies and pose a risk to long-term sustainability without significant improvements.

Negative Cash Flow

Negative cash flow highlights unsustainable operations, necessitating external funding and posing a risk to financial stability if not addressed.

Nasdaq Delisting Notice

The delisting notice from Nasdaq due to low stock price could impact investor confidence and limit access to capital markets, affecting long-term growth.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc. is a biotechnology company that focuses on developing plant-based biologics for the biopharmaceutical market. The company operates primarily in the sectors of biopharmaceutical development and manufacturing, utilizing its proprietary FastPharming System to produce vaccines and therapeutic proteins. iBio aims to provide more efficient and cost-effective solutions for biologics production, targeting areas such as oncology, fibrosis, and infectious diseases.

How the Company Makes Money

iBio generates revenue through its biopharmaceutical development initiatives and contract manufacturing services. The company's primary revenue streams include licensing agreements, where it licenses its FastPharming technology to other organizations, and contract development and manufacturing services, where it produces plant-based biologics for clients. Additionally, iBio may engage in strategic partnerships and collaborations to enhance its development pipeline and expand its market reach. The company also seeks to advance its proprietary therapeutic candidates, which, upon successful development and commercialization, could provide additional revenue through sales or out-licensing deals.

Ibio Financial Statement Overview

Summary

Ibio's financial health is challenged by consistent losses and declining revenue, despite some improvement in leverage ratios. Cash flow issues persist, requiring external funding to maintain operations. The company faces significant risks due to its high operational inefficiencies and ongoing cash burn.

Income Statement

The company shows a declining trend in revenue, with significant losses in net income and EBIT. The TTM Gross Profit Margin is inflated due to the inclusion of other income streams, but the core revenue remains weak. The negative EBIT and EBITDA margins indicate operational inefficiency and high expenses relative to revenue.

Balance Sheet

The company's debt-to-equity ratio has improved, indicating better leverage management, but overall equity is decreasing. The equity ratio shows a decline in shareholders' equity as a proportion of total assets, suggesting potential risk. Despite these issues, the company has managed to reduce liabilities over time.

Cash Flow

Operating cash flow remains negative, reflecting ongoing cash burn, though financing activities have temporarily supported liquidity. The free cash flow to net income ratio is unfavorable, highlighting unsustainable operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	375.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	1.12M	0.00	225.00K	-1.11M	2.17M	909.00K
EBITDA	-15.11M	-18.38M	-14.02M	-28.12M	-25.72M	-18.34M
Net Income	-20.99M	0.00	-24.91M	-29.31M	-51.01M	-23.21M
Balance Sheet
Total Assets	19.10M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	4.96M	8.58M	14.21M	4.30M	33.52M	96.97M
Total Debt	2.93M	2.74M	4.46M	17.07M	27.79M	32.72M
Total Liabilities	7.72M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	11.38M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-15.77M	-15.32M	-18.76M	-36.17M	-49.11M	-35.23M
Operating Cash Flow	-15.54M	-15.30M	-18.55M	-30.44M	-37.48M	-30.06M
Investing Cash Flow	553.00K	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	13.74M	8.93M	24.49M	2.30M	-6.13M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 0.96 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.75, and below the 200-day MA of 2.04, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 69.60 is Neutral, neither overbought nor oversold. The STOCH value of 80.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
ADXN	51 Neutral	$13.34M	0.72	-162.42%	―	-82.24%	―
PSTV	48 Neutral	$45.87M	―	249.03%	―	-3.49%	27.88%
IBIO	42 Neutral	$18.93M	―	-101.52%	―	77.78%	84.08%
AFMDQ	42 Neutral	$1.52K	―		―	-95.23%	42.16%
HOTH	―	$21.21M	―	-106.80%	―	―	―
RLYB	35 Underperform	$25.07M	―	-66.12%	―	154.52%	47.84%

Ibio Corporate Events

iBio Enters Licensing Agreement for Obesity Treatment

On April 21, 2025, iBio, Inc. entered into an exclusive licensing agreement with AstralBio, Inc. for a first-in-class antibody targeting Activin E, aimed at treating obesity and cardiometabolic diseases. This agreement allows iBio to develop, manufacture, and commercialize the antibody, which has shown promising preclinical results in inducing fat-selective weight loss and improving cardiometabolic health. The licensing deal involves an upfront fee and potential milestone payments up to $28 million, with iBio taking full responsibility for the product’s development and commercialization. This strategic move is expected to expand iBio’s pipeline and strengthen its position in the cardiometabolic and obesity treatment market.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, IBIO is a Underperform.

IBio faces significant financial challenges, with negative earnings and cash flow being major concerns. Technical analysis indicates weak momentum. While recent corporate events suggest potential for future growth, current financial and valuation issues heavily weigh down the stock, resulting in a low overall score.

To see Spark’s full report on IBIO stock, click here.

iBio Highlights Advancements in Obesity Antibody Programs

iBio, Inc. has updated its corporate presentation to highlight significant advancements in its antibody programs, particularly in obesity treatment. The updated data showcases the potential of IBIO-600, a long-acting anti-myostatin antibody, which demonstrated extended half-life and muscle growth in non-human primates, suggesting a long human half-life. Additionally, preclinical data on an Activin E antibody showed promising results in fat-selective weight loss and enhanced effects when combined with semaglutide, indicating a strong potential for addressing obesity and related metabolic conditions.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.

IBio’s stock score is primarily hindered by significant financial difficulties, including negative earnings and cash flow. Despite strong technical momentum, the negative valuation metrics and lack of profitability weigh heavily on the overall score. Recent corporate events indicate potential long-term growth, but they are not enough to offset the current financial and valuation concerns.

To see Spark’s full report on IBIO stock, click here.

iBio Reveals Promising Study Results for IBIO-600

On April 7, 2025, iBio announced promising data from a non-human primate study of its long-acting anti-myostatin antibody, IBIO-600, which showed potential for extended half-life and muscle growth. The study indicated that IBIO-600 could have a human half-life of up to 130 days, suggesting a reduced dosing schedule and positioning it as a best-in-class therapeutic for muscle preservation and weight loss. Additionally, preclinical data for a first-in-class Activin E antibody revealed significant fat-selective weight loss in obese mice, both as a monotherapy and in combination with semaglutide, highlighting its potential as a transformative obesity treatment.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, (IBIO) is a Neutral.

IBio’s overall score reflects a mix of significant financial challenges, balanced by strong technical momentum. The company’s negative earnings and cash flow are major concerns, but recent strategic initiatives and positive technical indicators provide some optimism. Valuation remains a hurdle due to negative profitability metrics.

To see Spark’s full report on (IBIO) stock, click here.

iBio Announces Transfer to Nasdaq Capital Market

On February 19, 2025, iBio, Inc. announced its decision to transfer the listing of its common stock from NYSE American to the Nasdaq Capital Market. The trading on NYSE American will end on March 3, 2025, with Nasdaq trading commencing on March 4, 2025, under the same ticker symbol ‘IBIO.’ The company believes this move will enhance visibility, trading liquidity, and exposure to institutional investors, aligning with its strategy to join a community of leading biotech firms.